Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that EGFR activating variants status confers therapeutic sensitivity to Osimertinib in patients with Non-Small Cell Lung Cancer.
The Republic of Ireland's Health Service Executive (HSE) has approved osimertinib for reimbursement as a monotherapy treatment option as a first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.
This statement is based on a regulatory approval from the Health Service Executive:
First-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.